Axovant Sciences Ltd (AXON.OQ)
Thu, Feb 15 2018
* AXOVANT SCIENCES LTD - ON FEBRUARY 12, INITIATED A CORPORATE REALIGNMENT THAT INCLUDED A REDUCTION IN ITS WORKFORCE - SEC FILING
Feb 12 Axovant Sciences Ltd on Monday said Chief Executive Officer David Hung had resigned, nearly a year after his appointment.
Axovant Sciences Ltd's shares fell nearly 50 percent on Monday after the company scrapped its intepirdine program following the failure of its lead experimental treatment in a mid-stage study on patients suffering from a type of dementia.
Jan 8 Axovant Sciences Ltd said on Monday it would discontinue its intepirdine program after the experimental treatment failed in a mid-stage study on patients suffering from a type of dementia.
BRIEF-Axovant Announces Negative Results For Intepirdine In Phase 2B Headway, Pilot Phase 2 Gait, Balance Studies
* AXOVANT ANNOUNCES NEGATIVE RESULTS FOR INTEPIRDINE IN PHASE 2B HEADWAY AND PILOT PHASE 2 GAIT AND BALANCE STUDIES; POSITIVE TRENDS IN EFFICACY SEEN IN PILOT PHASE 2 NELOTANSERIN STUDY
CORRECTED-BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
* AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT
* Axovant announces second fiscal quarter financial results and corporate updates
- vTv Therapeutics Fails Late-Stage Alzheimer's Study; Is There A Chance For A Comeback?
- Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data
- Celgene Vs. Biogen: Both Are A Steal, But Which One Is Better?
- Axovant Sciences: 5 Trials, 4 Failures - Expect A Fifth
- Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update
- Your Daily Pharma Scoop: Shire Looks Attractive, Omeros Data, Axovant Restructuring